No es el mismo pero ¿es igual? Cycling de agentes biológicos en artritis reumatoide. Experiencia en el Instituto Mexicano del Seguro Social
- 1 June 2022
- journal article
- Published by Elsevier in Reumatología Clínica
- Vol. 18 (6) , 361-367
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance DatabaseSeminars in Arthritis and Rheumatism, 2018
- Biosimilarity and Interchangeability: Principles and Evidence: A Systematic ReviewBioDrugs, 2018
- Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar InfliximabArthritis & Rheumatology, 2017
- A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registryAnnals of the Rheumatic Diseases, 2017
- Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the ClinicianCurrent Rheumatology Reports, 2017
- Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trialThe Lancet, 2017
- Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN StudyAdvances in Therapy, 2016
- Biological agents and biosimilars: Essential information for the internistEuropean Journal of Internal Medicine, 2016
- Indirect comparison of biological treatments in refractory rheumatoid arthritisJournal of Clinical Pharmacy and Therapeutics, 2011
- Medication Adherence: WHO Cares?Mayo Clinic Proceedings, 2011